Trial Profile
A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Myoclonic epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 08 Apr 2022 This trial has been completed in Spain (Global end date: 11-12-2008), according to European Clinical Trials Database record.
- 08 Apr 2022 This trial has been completed in Spain (Global end date: 11-12-2008), according to European Clinical Trials Database record.
- 31 Mar 2022 This trial has been completed in Czechia, according to European Clinical Trials Database record (Global end date 2008-12-11).